EGFR and glioblastoma: A phase I trial (NCT03603379) tested anti-EGFR immunoliposomes loaded with doxorubicin in recurrent EGFR-amplified GBM, yielding an 8-month median OS despite limited BBB penetration (Kasenda et al. 2022).